Findings from a phase II study indicate clinical efficacy with erdafitinib in 
patients with FGFR-altered inoperable or metastatic urothelial carcinoma. Robust 
responses were seen with this investigational pan-FGFR inhibitor, including in 
patients who did not respond to prior immunotherapy.